Maryland State Retirement & Pension System grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 440.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 14,395 shares of the medical research company’s stock after purchasing an additional 11,731 shares during the period. Maryland State Retirement & Pension System’s holdings in Charles River Laboratories International were worth $4,247,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Handelsbanken Fonder AB lifted its position in Charles River Laboratories International by 36.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock valued at $4,378,000 after acquiring an additional 5,200 shares in the last quarter. Avidity Partners Management LP bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth $1,670,000. Evergreen Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth $2,621,000. Quantitative Investment Management LLC bought a new stake in shares of Charles River Laboratories International in the 2nd quarter worth $1,360,000. Finally, Madison Asset Management LLC purchased a new position in shares of Charles River Laboratories International in the second quarter worth $3,805,000. Institutional investors own 98.91% of the company’s stock.
Insider Buying and Selling
In related news, EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 24,042 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $11,058,600. This trade represents a 43.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,352 shares of company stock valued at $20,291,281 over the last 90 days. Company insiders own 1.30% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on CRL shares. Argus set a $330.00 price target on Charles River Laboratories International in a report on Thursday, September 17th. Royal Bank Of Canada increased their price objective on Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a report on Monday, August 10th. Deutsche Bank boosted their target price on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Finally, Robert W. Baird upped their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $311.67.
View Our Latest Report on Charles River Laboratories International
Charles River Laboratories International Trading Up 0.1%
Shares of CRL stock opened at $338.27 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $379.63. The stock has a market capitalization of $16.21 billion, a P/E ratio of 371.73, a P/E/G ratio of 3.05 and a beta of 1.36. The firm’s 50 day moving average is $311.21 and its 200 day moving average is $228.24.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.12. The business had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.43 EPS. Research analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Further Reading
- Five stocks we like better than Charles River Laboratories International
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
